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Genomewide Association Analysis of Human Narcolepsy
and a New Resistance Gene
Minae Kawashima, Gen Tamiya, Akira Oka, Hirohiko Hohjoh,* Takeo Juji, Takashi Ebisawa,
Yutaka Honda, Hidetoshi Inoko, and Katsushi Tokunaga
Human narcolepsy is a hypersomnia that is affected by multiple genetic and environmental factors. One genetic factor
strongly associated with narcolepsy is the HLA-DRB1*1501-DQB1*0602 haplotype in the human leukocyte antigen region
on chromosome 6, whereas the other genetic factors are not clear. To discover additional candidate regions for suscep-
tibility or resistance to human narcolepsy, we performed a genomewide association study, using 23,244 microsatellite
markers. Two rounds of screening with the use of pooled DNAs yielded 96 microsatellite markers (including 16 markers
on chromosome 6) with signiﬁcantly different estimated frequencies in case and control pools. Markers not located on
chromosome 6 were evaluated by the individual typing of 95 cases and 95 controls; 30 markers still showed signiﬁcant
associations. A strong association was displayed by a marker on chromosome 21 (21q22.3). The surrounding region was
subjected to high-density association mapping with 14 additional microsatellite markers and 74 SNPs. One microsatellite
marker (D21S0012m) and two SNPs (rs13048981 and rs13046884) showed strong associations ( ; odds ratios 0.19–P ! .0005
0.33). These polymorphisms were in a strong linkage disequilibrium, and no other polymorphism in the region showed
a stronger association with narcolepsy. The region contains three predicted genes—NLC1-A, NLC1-B, and NLC1-C—
tentatively named “narcolepsy candidate-region 1 genes,” and NLC1-A and NLC1-C were expressed in human hypo-
thalamus. Reporter-gene assays showed that the marker D21S0012m in the promoter region and the SNP rs13046884 in
the intron of NLC1-A signiﬁcantly affected expression levels. Therefore, NLC1-A is considered to be a new resistance
gene for human narcolepsy.
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Narcolepsy (MIM 161400) typically appears, without sex-
ual difference, in early adulthood and affects 0.16%–
0.18% of the general population of Japan.1,2 The disorder
is characterized by excessive daytime sleepiness, cataplexy,
and pathological manifestation of rapid eye movement
(REM) sleep, including hypnagogic hallucinations, sleep
paralysis, or sleep-onset REM sleep. Most cases are spo-
radic, but the risk of the disorder for ﬁrst-degree relatives
of patients with narcolepsy is 1%–2%, ∼10 times greater
than the general risk of developing narcolepsy. Only about
a third of MZ twins are concordant for narcolepsy.2 There-
fore, human narcolepsy is considered to be amultifactorial
disorder, involving multiple genetic and environmental
factors.
A genetic susceptibility factor associated with the dis-
order has been found in the human leukocyte antigen
(HLA) class II region: the HLA-DRB1*1501-DQB1*0602
haplotype (HLA-DRB1 [MIM 142857] and HLA-DQB1
[MIM 604305]). Although almost all Japanese patients
with narcolepsy carry this haplotype, ∼10% of the general
Japanese population also carries it, suggesting that this
haplotype is neither necessary nor sufﬁcient for the de-
velopment of narcolepsy.1,3–5 This conclusion is also sup-
ported by another line of reasoning. The penetrance and
population frequency of HLA-DRB1*1501 were estimated
with the formula described by Ohashi et al.,8 based on the
prevalence of narcolepsy in the Japanese population
(0.16%–0.18%)1,2 and the results of a case-control associ-
ation study of this haplotype.7 On the basis of these values
and with the formula described by James9 and by Risch,10
the expected ls value for HLA of Japanese patients with
narcolepsy was calculated to be 5.15, much less than the
ls of 12 reported for narcolepsy.6 Therefore, genes other
than HLA are also expected to contribute to the disease
susceptibility.
Several candidate regions11–13 and genes14,15 other than
HLA have been investigated for association with human
narcolepsy involving cataplexy (narcolepsy-cataplexy)
and daytime sleepiness. Nevertheless, replicated associa-
tions are few, except for tumor necrosis factor-a (TNFA
[MIM 191160]) and TNF-receptor 2 (TNFR2 [MIM
191191]).16–20 In autosomal recessive canine models that
develop narcolepsy-cataplexy with full penetrance, an in-
sertion in the hypocretin (orexin)–receptor type 2 gene
(HCRTR2 [MIM 602393]) was found to be responsible for
the disorder,21 and preprohypocretin-knockout mice ex-
hibit a phenotype similar to narcolepsy-cataplexy.22 For
human narcolepsy, which shows multifactorial inheri-
tance, as described above, the hypocretin concentration
in cerebrospinal ﬂuid was reduced or undetectable in spo-
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radic narcolepsy,23 and the number of hypothalamic hy-
pocretin neurons was decreased in postmortem narco-
leptic brains.24,25 Although the preprohypocretin (MIM
602358) and hypocretin-receptor genes have been ex-
amined for possible association with human narcolepsy,
variants in these genes were not detected in most human
patients with narcolepsy.26–28 Therefore, human narco-
lepsy cannot be explained by mutations in preprohypo-
cretin and hypocretin-receptor genes.
There is evidence for a role of autoantibodies in nar-
colepsy. Recently, mice were injected with puriﬁed im-
munoglobulin G (IgG) fraction from the serum of nine
patients who have narcolepsy-cataplexy with the HLA-
DQB1*0602 haplotype. These mice exhibited stresslike be-
haviors, such as crouching posture and piloerection, and
narcoleptic-like behavior, such as brief behavioral pauses
lasting from a few seconds to a minute during periods of
activity.29 Another group revealed that IgG in the cere-
brospinal ﬂuid of HLA-DQB1*0602–positive patients with
narcolepsy-cataplexy binds to rat hypothalamic pro-
teins.30 These two reports suggested that cerebrospinal
ﬂuid and serum from patients with narcolepsy contain
functional autoantibodies that contribute to the patho-
genesis of narcolepsy. However, the pathophysiological
mechanism and genetic factors underlying human nar-
colepsy remain unknown.
For this study, we performed a genomewide association
study, using 23,244 microsatellite markers for the detec-
tion of susceptibility/resistance regions to narcolepsy.
This strategy is expected to be effective in the search for
candidate regions throughout the whole genome, because
of the high detection power of case-control association
studies.31,32 Microsatellite markers are abundant and in-
terspersed throughout the human genome. Compared
with SNPs, microsatellite markers display higher degrees
of polymorphisms: multiple alleles exhibit high levels of
heterozygosity, so a smaller number of microsatellite
markers may provide a reasonable statistical power in as-
sociation analyses.33,34 Moreover, to reduce the genotyping
cost and labor, genomic DNA samples were pooled33,35 in
the ﬁrst and second screenings. We demonstrated else-
where that this strategy can detect the known association
with the HLA region; using 1,265 microsatellite markers
on chromosome 6, we detected strong associations be-
tween multiple microsatellite markers in the HLA region
and human narcolepsy.36 Here, we extend the strategy to
the other chromosomes, using 21,979 additional micro-
satellite markers.
Material and Methods
Patients and Unaffected Individuals
All patients and unaffected individuals were unrelated Japanese
adults living in Tokyo or neighboring areas. Genomic DNAs were
obtained from 370 patients given a diagnosis of narcolepsy-cat-
aplexy at the Sleep Disorders Clinic of Seiwa Hospital. All patients
with narcolepsy carried the HLA-DRB1*1501-DQB1*0602 haplo-
type. These 370 genomic DNAs were divided randomly into three
sets (the ﬁrst and second sets with 110 samples each and the third
set with the remaining 150 samples). The control group com-
prised 610 unrelated unaffected individuals and an additional125
individuals positive forHLA-DRB1*1501. The 610 control samples
were also divided into three sets (210 samples each in the ﬁrst
and second sets and the remaining 190 samples in the third set).
Genomic DNAs were puriﬁed from peripheral blood, with the use
of a commercial kit (QIAamp Blood Kit [Qiagen]). This study was
approved by the research ethics review committees of the Uni-
versity of Tokyo and the Neuropsychiatric Research Institute,
which runs Seiwa Hospital.
Preparation of Pooled DNA Samples
Genomic DNA concentration was measured in triplicate, in ac-
cordance with the methods of Collins et al.,37 with the use of a
double-stranded DNA quantiﬁcation kit (PicoGreen [Molecular
Probes]) with a microtiter plate reader (SF600 Corona Electric).
Genomic DNAs were adjusted to 8 ng/ml. DNAs from 110 patients
with narcolepsy and from 210 controls were then mixed, for the
ﬁrst set of case and control pools, named “case-1” and “control-
1,” respectively.38 The second set of pooled DNA (case-2 and con-
trol-2) was also prepared from another 110 cases and 210 controls.
Analyses of Microsatellite Polymorphisms for Genomewide
Screening
All microsatellite markers and the methods for microsatellite
analysis used in this study are described by Tamiya et al.33 In brief,
PCR primers were designed for amplifying fragments that include
the microsatellite polymorphisms. All PCR primers were designed
to have an annealing temperature of 57C. Forward primers were
labeled at the 5′ end with ﬂuorescent reagent (6-FAM or HEX
[Applied Biosystems]). PCR on pooled DNAs was performed in
20-ml reactions containing 48 ng of pooled DNA, 0.5 units of DNA
polymerase (AmpliTaq [Applied Biosystems]), 1# reaction buffer
with 1.5 mM MgCl2 provided by the manufacturer (Applied Bio-
systems), 5 mM of each primer, and 0.25 mM of each deoxyri-
bonucleotide triphosphate (dNTP) in 96- or 384-well plates. The
ampliﬁcation condition consisted of initial denaturation at 96C
for 5 min (hot start), annealing at 57C for 1 min, and extension
at 72C for 1 min, followed by 40 cycles of denaturation at 96C
for 45 s, annealing at 57C for 45 s, and extension at 72C for 1
min, with use of a thermal cycler (GeneAmp PCR system 9700
[Applied Biosystems]).
For microsatellite typing of individual samples, PCR was per-
formed in 12-ml reactions containing 2 ng of genomic DNA, 0.25
units of DNA polymerase (AmpliTaq Gold [Applied Biosystems]),
1# reaction buffer with 1.5 mM MgCl2 provided by the manu-
facturer, 5 mM of each primer, and 0.2 mM of each dNTP in 96-
or 384-well plates. The ampliﬁcation conditions were essentially
the same as described above.
The PCR products were denatured in formamide (Hi-Di [Ap-
plied Biosystems]) at 95C for 3 min and were separated by elec-
trophoresis, with the use of an automated DNA sequencer with
size standards (ABI Prism 3700 Genetic Analyzer, ROX size stan-
dard [Applied Biosystems]). The fragment size and the electro-
phoretograms were analyzed by GeneScan and Genotyper soft-
ware (Applied Biosystems).
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Additional Microsatellite Markers for High-Density
Association Mapping
To obtain additional microsatellite markers in the narcolepsy can-
didate–region 1 (NLC1), the sequence of the candidate region
was obtained from the University of California–Santa Cruz
(UCSC) Genome Browser database (November 2002 version,
based on NCBI Build 31). Then, the sequence was searched for
repeated elements with the RepeatMasker program. Dinucleotide
repeats with repeat number 112, trinucleotide repeats 18, and
tetranucleotide to hexanucleotide repeats 15 were chosen. PCR
primers were designed as described above, and we evaluated the
polymorphism of eachmicrosatellite with pooledDNA, searching
for multiple peaks in the electrophoresis.
SNP Analyses
SNPs within the candidate region were selected from the Celera
database at average intervals of ∼5 kb, and speciﬁc PCR primers
were designed. To conﬁrm the polymorphisms of these SNP sites
in the Japanese population, we examined 16 samples from pa-
tients with narcolepsy by direct sequencing, using a PCR cycle-
sequencing kit and an automated DNA sequencer (BigDye Ter-
minator v.3.1 Cycle Sequencing Kit and ABI PRISM 3730 DNA
sequencer [Applied Biosystems]). The association analyses with
these polymorphic sites were performed by direct sequencing of
case and control samples.
The sequence of the entire region of NLC1-A, NLC1-B, and
NLC1-C genes (based on NCBI Build 35 chromosome 21:
45234058–45250151) was also screened for polymorphisms with
16 samples, and polymorphic sites were subjected to association
analyses by direct sequencing of case and control samples. Newly
detected polymorphisms have been registered in the dbSNP
database.
Expression Analysis by RT-PCR
The expression of the predicted genes in candidate region NLC1
was examined by RT-PCR, with the use of poly(A) RNA from the
human brain, hypothalamus, peripheral blood, sperm, and sev-
eral organs (i.e., heart, liver, spleen, pancreas, lung, kidney, and
skeletal muscle [Bio Chain]). To discriminate PCR products de-
rived from reverse-transcribed mRNA from those derived from
genomic DNA, we designed speciﬁc forward and reverse primers
in the predicted exon 1 and 2 regions, respectively. The primer
sets for the predicted genes were as follows: 5′-CTAGGAGGGGAA-
ACTGAGTCC-3′ and 5′-CAGCACAGTTGGAGACATCACT-3′ for
NLC1-A, 5′-CCTCACAGCATCCCACATT-3′ and 5′-TTTCTGGAAA-
CAGCCAGGAG-3′ for NLC1-B, and 5′-GCTGAACTGCCTGGACT-
TTC-3′ and 5′-ACATGTGCTCCCCACCTAAG-3′ for NLC1-C. The
thermal cycling proﬁle consisted of initial denaturation at 96C
for 10 min, followed by 35 cycles of denaturation at 96C for 45
s, annealing at 57C for 45 s, extension at 72C for 1 min, and a
ﬁnal extension at 72C for 5 min, with the use of AmpliTaq Gold
polymerase (Applied Biosystems). The PCR products were sepa-
rated by electrophoresis on 2% agarose gels andwere stainedwith
ethidium bromide. The sequences of the ampliﬁed products were
conﬁrmed by direct sequencing.
Reporter-Gene Assay
Reporter-gene assays were performed using constructs containing
microsatellitemarkerD21S0012m and SNP rs13046884 alleles. For
D21S0012m, genomic DNAs were obtained from four homozy-
gotes for alleles with AC repeat numbers 8, 9, 10, and 12. A 908-
bp fragment within the promoter region including D21S0012m
was ampliﬁed by PCR, with use of the speciﬁc primers 5′-CAAAG-
GTACCTCCAGTCCACACCCACC-3′ and 5′-GTTTGAGCTCTTTG-
GCCTGTCCATCAG-3′. Genomic DNA for SNP rs13046884 alleles
was obtained from one rs13046884 heterozygote. A 297-bp frag-
ment within NLC1-A intron 1, which includes rs13046884, was
ampliﬁed using primers 5′-CAAAGGTACCAGGGTTGGACTCC-
AAAGGGA-3′ and 5′-GTTTGAGCTCGGGTGACTTCTTCACA-
CCCA-3′. PCR was performed (TaKaRa LA Taq [TaKaRa]) with the
following thermal cycling proﬁle: denaturation at 96C for 5min,
followed by 35 cycles at 96C for 30 s, 60C for 30 s, and 72C
for 1.5 min. PCR products were digested with SacI and KpnI re-
striction endonucleases and then were inserted upstream of a
ﬁreﬂy luciferase gene in the pGL3-control vector (Promega), with
the use of T4 DNA ligase (TaKaRa). Inserted sequences were con-
ﬁrmed by direct sequencing with primers speciﬁc to the pGL3-
control vector (5′-CATACGCTCTCCATCAAAACAA-3′ and 5′-
AAGCCTCCTCACTACTTCTGGA-3′). The neuroblastoma cell line
NB-1 and HeLa cells were maintained in accordance with pub-
lished recommendations (Human Science Research Resources
Bank). Then, 0.2 mg of each construct was introduced into the
cells by a lipofection method (Effectene Transfection Reagent
[Qiagen]), along with 0.02 mg of pRL-SV40 (Promega) as an in-
ternal control. Luciferase levels were determined using theDUAL-
Luciferase Reporter Assay System (Promega), and ﬁreﬂy luciferase
levels were normalized to the levels of renilla luciferase frompRL-
SV40.
Statistical Analyses
Disease associations with polymorphisms were assessed by
Fisher’s exact test, with the use of 2#2 contingency tables for
each allele. The smallest P value for each marker was selected.
Allele frequencies in pooled-DNA typing were estimated from the
height of peaks: each allele frequency was determined by dividing
the height of each allele by the summed height of all alleles. In
individual typing, the signiﬁcance was evaluated by Fisher’s exact
test, with the use of 2#m (where m is the number of alleles) and
2#2 contingency tables. The signiﬁcance level was set at .05
throughout this study, except for homogeneity among samples
used in the ﬁrst, second, and third set, which was tested bymeans
of the Q statistic and was considered signiﬁcant for .39P ! .10
To assess the extent of pairwise linkage disequilibrium (LD)
between polymorphisms, Lewontin’s40 D′ and r2 were calculated
using a commercial software package (SNPAlyze-3.2 pro [Dyna-
com]) based on the expectation-maximation algorithm. D′ and r2
were calculated only for polymorphisms with a minor-allele fre-
quency (MAF) 16%. Pairwise D′ and r2 were plotted at the Car-
tesian coordinate corresponding to the polymorphism location
on the physical map with the use of the GOLD program, as de-
scribed by Abecasis and Cookson.41
Results
Genomewide Association Study
The 23,244 microsatellite markers used in the genome-
wide association study are summarized in table 1. To re-
duce the cost and the technical burden of genomewide
association analysis, the DNA-pooling method was ap-
plied in the ﬁrst and second screenings (ﬁg. 1A). Allele
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Table 1. Numbers and Mean Intervals
of Microsatellite Markers on Each
Chromosome
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
frequencies were estimated from the height of individual
peaks. To avoid false-negative associations, we performed
no correction for multiple comparisons. Figure 1B shows
the results of the association analyses in the ﬁrst screening;
the results for the 1,265 microsatellite markers on chro-
mosome 6, which includes theHLA region, were described
elsewhere.36 A total of 2,686 markers (202 of which were
on chromosome 6) showed signiﬁcantly different fre-
quencies between cases and controls. These 2,686markers
were further analyzed in the second screeningwith pooled
DNA samples from different sets of cases and controls, and
96 markers (16 on chromosome 6) remained signiﬁcantly
different between cases and controls and had similar peak
patterns between ﬁrst and second case pools and between
ﬁrst and second control pools.
To conﬁrm the associations observed, we subjected the
80 microsatellite markers located outside of chromosome
6 to individual typing with 95 case and 95 control sam-
ples, which were randomly chosen from the samples used
in the ﬁrst and second pools. Thirty markers still showed
statistically signiﬁcant differences by Fisher’s exact test,
with the use of 2#2 contingency tables (ﬁg. 1A and 1B
and table 2). In particular, 11 microsatellite markers also
showed differences in allele frequencies with the use of
2#m contingency tables. The remaining samples that
were used in the ﬁrst and second screenings (125 cases
and 325 controls) were also genotyped for those 11 mark-
ers, and all the markers still reached a signiﬁcant level. In
addition, the smallest P values calculated by Fisher’s exact
test, with the use of 2#2 contingency tables in the pooled-
DNA genotyping (ﬁrst and second screenings), were re-
ﬂected by the smallest P values in the individual geno-
typing with 220 cases and 420 controls.
One of the strong associations with narcolepsy was dis-
played by the microsatellite marker D21S0241i, located
on 21q22.3 (based on NCBI Build 35 chromosome 21:
45169766–45169825; [AAGG]7–17). The frequency of the
(AAGG)10 allele was 8.6% among cases and 4.0% among
controls ( ; odds ratio [OR] 2.24; 95% CI 1.40–Pp .0012
3.58). To further conﬁrm the association, we tested
D21S0241i for association in a third set of individuals not
used in either of the pools (150 cases and 190 controls).
Signiﬁcant association was not observed in this set (Pp
; OR 2.11; 95% CI 0.88–5.06), but no heterogeneitywas.12
detected among the three sets of cases or controls by the
Q statistic ( ), and the allele frequencies in the thirdPp .92
set displayed the same general pattern among cases com-
pared with controls as they did in the ﬁrst and second
sets. Moreover, the signiﬁcant association was still ob-
served when the association analysis was performed by
individual genotyping of the three sets of case and control
samples ( ; OR 2.08; 95% CI 1.38–3.13) (tablePp .00064
3). Taken together, these observations indicate thatmarker
D21S0241i is associated with human narcolepsy.
High-Density Association Mapping with Additional
Microsatellite Markers and SNPs
We analyzed the region surrounding the marker
D21S0241i by high-density association mapping with
additional microsatellite markers. To develop additional
markers, we searched the surrounding genomic sequence
for microsatellites. Polymorphisms of individual micro-
satellites were detected using pooled DNA samples, and
14 new microsatellite markers were established within
652 kb around marker D21S0241i (ﬁg. 2A). These markers
were analyzed in 220 case and 440 control samples (ta-
ble 4). The new marker, D21S0012m (chromosome 21:
45238835–45238862), which is 70 kb from D21S0241i,
showed a stronger association than D21S0241i (frequen-
cies of the [AC]10 allele: cases 0.9%, controls 4.6%; Pp
; OR 0.19; 95% CI 0.074–0.48)..00023
Next, to further deﬁne the candidate region, we per-
formed high-density mapping with SNPs (listed in appen-
dix A [online only]). To cover a 171-kb region around the
markers D21S0241i and D21S0012m, we selected, from
databases, SNPs at ∼5-kb intervals. Direct sequencing on 16
cases (8 homozygotes and 8 heterozygotes of D21S0012m
allele [AC]10) was performed to screen for the SNPs. In
total, 64 registered SNPs and 10 novel ones were identiﬁed
and were subjected to association analyses with 190 cases
and 190 controls (ﬁg. 2B). Of the SNPs near D21S0241i,
only one (rs12483718) showed a signiﬁcant difference be-
tween cases and controls, whereas eight SNPs located close
to D21S0012m showed signiﬁcant differences. The stron-
gest association with narcolepsy was exhibited by SNPs
rs13048981 and rs13046884, both located close to
D21S0012m (for rs13048981, , OR 0.17, and 95%Pp .0016
CI 0.057–0.51; for rs13046884, , OR 0.16, andPp .0010
95% CI 0.055–0.48) (see ﬁg. 3). The SNPs rs13048981 and
rs13046884were further typed for all the available samples
(370 cases and 610 controls). The results for rs13048981
were , OR 0.31, and 95% CI 0.16–0.60; the re-Pp .00039
sults for rs13046884 were , OR 0.33, and 95%Pp .00036
CI 0.18–0.62 (table 3). The two SNPswere further analyzed
in 125 independently collectedHLA-DRB1*1501–positive
unaffected controls. Both SNPs again exhibited signiﬁcant
associations in the 370 cases comparedwith these controls
(for rs13048981, , OR 0.33, and 95%CI 0.14–0.77;Pp .017
for rs13046884, , OR 0.36, and 95% CI 0.16–0.83)Pp .023
(table 3). Therefore, we considered this region to be a can-
didate region for susceptibility/resistance to human nar-
colepsy and tentatively named the region “narcolepsy
candidate–region 1 (NLC1).”
The LD structure in this region was analyzed using the
SNPs with MAFs 16%, and one large LD block was found
(ﬁg. 3A and 3B). SNPs rs13048981 and rs13046884 and
Figure 1. Genomewide association analyses with 23,244 microsatellite markers. A, Flow chart of this study. a, MS p microsatellite
marker. b, Sixteen MSs on chromosome 6 and 80 MSs on other chromosomes showing reproducible peak patterns and remaining signiﬁcantly
different between cases and controls. c, Selected randomly from the samples used in the ﬁrst and second screenings. d, Eleven MSs
reaching signiﬁcance in both 2#2 and 2#m contingency tables. e, All samples used in ﬁrst and second screenings. B, Results of
genomewide screening. The ﬁgure shows P values by Fisher’s exact test based on 2#2 contingency tables (green line) or on 2#m
contingency tables (red line) in the ﬁrst screening. Yellow circles indicate 30 MSs that showed signiﬁcant associations in both ﬁrst
and second screenings and in individual typing.
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Table 2. Thirty Microsatellite Markers Showing Signiﬁcant Association
in the First and Second Screenings and in the Subsequent Individual
Genotyping
Marker Chromosome
P
Pooled DNAa
95 Cases and
95 Controls
220 Cases and
420 Controls
First Second 2#2b 2#mc 2#2b 2#mc
D1S0500i 1q23.1 .046 .00024 .017 .28 … …
D1S0583i 1q32.2 .038 .049 .018 .11 … …
D1S1208i 1q32.2 .045 .045 .029 .034 .0010 .0027
D1S1148i 1q31.2 .025 .047 .018 .073 … …
D2S303 2p14 .045 .017 .021 .19 … …
D2S0878i 2p16.2 .0011 .025 .0023 .0020 .0010 .00073
D3S0502i 3p22.2 .019 .036 .037 .15 … …
D3S0971i 3q22.2 .037 .016 .031 .23 … …
D3S0978i 3q24 .0031 .0047 .0044 .041 .0081 .13
D3S1174i 3p14.1 .044 .027 .022 .0084 .0021 .0013
G08391 4p15.1 .041 .047 .044 .16 … …
D4S0140i 4p15.1 .0027 .037 .0023 .0067 .0020 .0070
D4S0424i 4p16.3 .038 .036 .049 .63 … …
D5S0022i 5q32 .012 .0084 .0040 .016 .011 .0017
D5S0565i 5p13.3 .0051 .013 .0031 .052 … …
D7S0486i 7p15.2 .036 .0020 .049 .68 … …
D7S0760i 7p11.2 .0044 .0040 .016 .086 … …
D7S1066i 7q11.22 .0089 .028 .011 .095 … …
D8S0068i 8 .018 .034 .011 .30 … …
D8S0584i 8q24.21 .012 .012 .018 .11 … …
D14S0284i 14q31.3 .0030 .049 .0058 .018 .027 .38
D15S150 15q21.3 .020 .049 .024 .21 … …
D15S0157i 15q21.3 .019 .0088 .010 .16 … …
D17S1300 17q24.3 .022 .0071 .036 .13 … …
D17S0179i 17 .0044 .050 .018 .0090 .0016 .0060
D17S0306i 17p11.2 .0060 .021 .011 .014 .0069 .076
D20S0027i 20p11.21 .0055 .014 .024 .18 … …
D21S0098i 21q21.1 .023 .0044 .00029 .0051 .00031 .011
D21S0241i 21q22.3 .018 .00043 .0098 .018 .0012 .048
DXS0660i Xp22.13 .00061 .0080 .0025 .065 … …
a P values calculated by Fisher’s exact test, based on 2#2 contingency tables with
estimated allele frequencies. The smallest P value was selected. The alleles that showed
the smallest P values in the pooled DNA genotypings were reﬂected in the individual
genotyping.
b P values calculated by Fisher’s exact test, based on 2#2 contingency tables. The
smallest P value was selected.
c P values calculated by Fisher’s exact test, based on 2#m contingency tables.
microsatellite marker D21S0012m were in the same LD
block, whereas D21S0241i was not. In addition, the
rs13046884 g allele, the rs13048981 t allele, and the
D21S0012m (AC)10 allele were found to be in strong LD
( ), and the estimated haplotype frequency was2r 1 0.94
4.5% in the controls.
The region around the three polymorphisms contains
three predicted genes registered in the UCSC Genome
Browser, each of which is supported by between two
and ﬁve mRNAs or ESTs (ﬁg. 2C). These predicted genes
are on the reverse strand on chromosome 21q22.3,
with positions as follows: NLC1-A 45234209–4523842,
NLC1-B 45238709–45239923, and NLC1-C 45243550–
45249070 (Genome Browser accession numbers BC036902,
BC009635, and BC027456, respectively). According to the
UCSC Genome Browser, NLC1-A produces two alterna-
tively spliced transcripts encoding different protein iso-
forms; the position of the short isoform is 45235619–
45238383. The functions of these predicted genes are
currently unknown.
We performed further variation screening on the three
genes by direct sequencing with 16 samples, and 26 poly-
morphisms were observed. Fourteen of the polymor-
phisms were new: eight SNPs in NLC1-A, two in NLC1-B,
and four inNLC1-C.Next, these new polymorphismswere
subjected to association analysis with 190 cases and 190
controls (ﬁg. 2C). Four SNPs reached signiﬁcance in the
analysis, but none was stronger than rs13048981 or
rs13046884, indicating that these two SNPs, as well as
D21S0012m, are associated primarily in this region.
Table 3. Association Analyses of D21S0241i, D21S0012m, rs13048981, and
rs13046884 with 370 Patients with Narcolepsy and 610 Unaffected Controls
Marker or SNP and Allele
No. (%) of Individuals
Patients with
Narcolepsy
( )np 370
Control
Individuals
( )np 610
DRB1*1501-Positive
Control Individuals
( )np 125
D21S0241i:
(AAGG)7 0 (.0) 1 (.1) …
(AAGG)8 0 (.0) 1 (.1) …
(AAGG)9 1 (.1) 0 (.0) …
(AAGG)10
a 51 (6.9) 42 (3.4) …
(AAGG)11 65 (8.8) 90 (7.4) …
(AAGG)12 155 (20.9) 258 (21.1) …
(AAGG)13 154 (20.8) 249 (20.4) …
(AAGG)14 195 (26.4) 359 (29.4) …
(AAGG)15 94 (12.7) 180 (14.8) …
(AAGG)16 24 (3.2) 35 (2.9) …
(AAGG)17 1 (.1) 5 (.4) …
D21S0012m:
(AC)8 127 (17.2) 168 (13.8) …
(AC)9 447 (60.4) 762 (62.5) …
(AC)10
b 12 (1.6) 54 (4.4) …
(AC)11 36 (4.9) 48 (3.9) …
(AC)12 117 (15.8) 188 (15.4) …
(AC)13 1 (.1) 0 (.0) …
rs13048981:
Genotypec,d:
CC 360 (97.3) 561 (92.0) 115 (92.0)
CT 10 (2.7) 47 (7.7) 10 (8.0)
TT 0 (.0) 2 (.3) 0 (.0)
Allelee,f:
C 730 (98.6) 1,169 (95.8) 240 (96.0)
T 10 (1.4) 51 (4.2) 10 (4.0)
rs13046884:
Genotypeg,h:
AA 359 (97.0) 559 (91.6) 115 (92.0)
AG 11 (3.0) 49 (8.0) 10 (8.0)
GG 0 (.0) 2 (.3) 0 (.0)
Allelei,j:
A 729 (98.5) 1,167 (95.7) 240 (96.0)
G 11 (1.5) 53 (4.3) 10 (4.0)
a OR 2.08; 95% CI 1.4–3.1; .Pp .00064
b OR 0.36; 95% CI 0.2–0.7; .Pp .00068
c (patients with narcolepsy compared with controls, by Fisher’s exact test basedPp .00095
on a 2#3 contingency table).
d (patients with narcolepsy compared with DRB1*1501-positive controls, byPp .016
Fisher’s exact test based on a 2#3 contingency table).
e OR 0.31; 95% CI 0.16–0.60; (patients with narcolepsy compared with controls,Pp .00039
by Fisher’s exact test based on a 2#2 contingency table).
f OR 0.33; 95% CI 0.14–0.77; (patients with narcolepsy compared withPp .017
DRB1*1501-positive controls, by Fisher’s exact test based on a 2#2 contingency table).
g (patients with narcolepsy compared with controls, by Fisher’s exact test basedPp .0011
on a 2#3 contingency table).
h (patients with narcolepsy compared with DRB1*1501-positive controls, byPp .022
Fisher’s exact test based on a 2#3 contingency table).
i OR 0.33; 95% CI 0.18–0.62; (patients with narcolepsy compared with controls,Pp .00036
by Fisher’s exact test based on a 2#2 contingency table).
j OR 0.36; 95% CI 0.16–0.83; (patients with narcolepsy compared withPp .023
DRB1*1501-positive controls, by Fisher’s exact test based on a 2#2 contingency table).
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Table 4. Association Analyses with High-
Density Microsatellite Markers around
Marker D21S0241i
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
Figure 2. High-density mapping with additional microsatellite markers and SNPs. A, Association analyses using high-density micro-
satellite markers with 220 cases and 420 controls. Unblackened circles indicate microsatellite markers used in the ﬁrst and second
screenings. Blackened circles indicate microsatellite markers newly developed for the high-density mapping. The dark line shows the
P values calculated by Fisher’s exact test based on 2#2 contingency tables, whereas the lighter line shows those from 2#m contingency
tables. B, Association analyses using SNPs with 190 cases and 190 controls. The X-axis indicates the distance from D21S0012m. SNP
rs12483718 is located near D21S0241i. The Y-axis shows the P values calculated by Fisher’s exact test based on 2#2 contingency
tables. Two SNPs, rs13048981 and rs13046884, showed the strongest associations in the NLC1 region. C, Variation screening and high-
density association analyses in the NLC1 region. Top, Exon-intron structures of NLC1-A, NLC1-B, and NLC1-C. Boxes indicate exons, with
unblackened boxes indicating untranslated regions and blackened boxes indicating coding regions. Predicted gene regions and 1 kb of
upstream region were screened for sequence variations. Fourteen additional polymorphisms, including two nonsynonymous substitutions,
were detected and were examined for possible associations, but no polymorphisms showed stronger association than D21S0012m,
rs13048981, and rs13046884. Bottom, P values for individual SNPs.
Expression Analyses
We assessed the expression of these three predicted genes
in the human brain, hypothalamus, and other organs by
RT-PCR, using speciﬁc primers (ﬁg. 4A). Products with the
expected size were ampliﬁed for NLC1-A and NLC1-C in
whole brain and hypothalamus (ﬁg. 4B and 4C).Moreover,
direct sequencing of the products conﬁrmed that the cor-
rect sequence was ampliﬁed. However, for NLC1-B, the
ampliﬁed band was from genomic DNA, not from cDNA.
These observations indicate that NLC1-A and NLC1-C
were expressed in human whole brain and hypothalamus,
whereas NLC1-B was not. Notably, NLC1-A was also ex-
pressed in human spleen, lung, kidney, and skeletal mus-
cle, andNLC1-Cwas also expressed in human spleen, pan-
creas, lung, and sperm (ﬁg. 4C), but neither was expressed
in peripheral blood (data not shown). SNP rs13046884 is
in NLC1-A intron 1, and D21S0012m is 424 bp upstream
of the transcriptional start site of NLC1-A, which suggests
that NLC1-A may be a susceptibility/resistance gene for
human narcolepsy. SNP rs13048981 is located 2,602 bp
upstream of NLC1-B, which was not expressed in human
brain, and its position, 4,164 bp upstream ofNLC1-A, sug-
gests that its association with narcolepsy resulted merely
from the LD with rs13046884 and D21S0012m. Thus, it
is unlikely that NLC1-B is a susceptibility/resistance gene
for human narcolepsy.
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Figure 3. LD block structure. The legend is available in its en-
tirety in the online edition of The American Journal of Human
Genetics.
Figure 4. Expression analysis for NLC1-A, NCL1-B, and NCL1-C,
with the use of RT-PCR. A, Schematic drawing of the speciﬁc prim-
ers for RT-PCR. B, Expected size of RT-PCR products from cDNA or
genomic DNA. On the basis of the UCSC Genome Browser, products
with the expected size were ampliﬁed from cDNA for NLC1-A and
NLC1-C in samples of whole brain, hypothalamus, and several other
organs, but, for NLC1-B, only the products from genomic DNA were
observed (C). Ampliﬁed products were conﬁrmed by direct se-
quencing. Lane 1, Heart; lane 2, liver; lane 3, spleen; lane 4,
pancreas; lane 5, lung; lane 6, whole brain; lane 7, hypothalamus;
lane 8, kidney; lane 9, skeletal muscle; lane 10, sperm. NC p
negative control. M p 100-bp ladder size marker.
To test whether polymorphisms rs13046884 and
D21S0012m directly inﬂuence the transcription level of
NLC1-A,we performed reporter-gene assays. Six constructs
carrying different alleles of D21S0012m or rs13046884
were prepared from individuals with D21S0012m (CA)8,
(CA)9, (CA)10, and (CA)12 repeats or the rs13046884 a/g
genotype. These constructs were introduced into NB-1 or
HeLa cells, and the expression of luciferase was examined
in three independent experiments. The differences of tran-
scriptional activity were assessed by t test. The luciferase
activities of each construct were divided by the ones of
empty vector. These values were used for the t test. Figure
5 shows that the luciferase activities of reporters carrying
the resistance alleles (g allele of rs13046884 and [AC]10
allele of D21S0012m) were 1.5- to 2-fold lower than those
of other reporters in both NB-1 and HeLa cells, and the
differences assessed by t test reached statistical signiﬁ-
cance (for NB-1 cell, –6.7 and –.0010; fortp 2.4 Pp .039
HeLa cell, –74.7 and –.000000096). Thus,tp 6.9 Pp .0034
the promoter activity of NLC1-A is likely to be reduced
in individuals who possess the haplotype D21S0012m
(AC)10–rs13046884 g.
Discussion
We have systematically performed the ﬁrst genomewide
association analyses, to our knowledge, for detecting sus-
ceptibility or resistance genes to human narcolepsy, using
23,244 microsatellite markers. After two separate screen-
ings with pooled DNA samples, followed by individual
genotyping with 95 case and 95 control samples of 80
initial candidate markers located outside chromosome 6,
30 microsatellite markers remained as candidates for as-
sociation with narcolepsy. Among them, one marker
(D21S0241i) was further analyzed with a third set of cases
and controls, to conﬁrm the association. Although the
difference between cases and controls in the third set did
not reach statistical signiﬁcance, the allele frequencies
were similar to those in the ﬁrst and second sets. More-
over, a signiﬁcant association was detected in an analysis
of all the available samples (370 cases and 610 controls).
In an analysis of the region surrounding D21S0241i, one
microsatellite marker (D21S0012m) and eight nearby
SNPs, all located ∼70 kb from D21S0241i, were signiﬁ-
cantly associated with narcolepsy. D21S0012m and two of
the SNPs were the markers most strongly associated with
narcolepsy (all ); these three polymorphisms areP ! .0005
in strong LD. The genomic region including these three
polymorphisms is, therefore, a candidate region for hu-
man narcolepsy, which we tentatively designated “NLC1.”
For each of the three strongly associated polymorphisms,
a minor allele displayed signiﬁcantly reduced frequency
in patients with narcolepsy compared with controls (OR
0.19–0.33), which suggests that these alleles confer resis-
tance to narcolepsy.
NLC1 is located on 21q22.3, 2.6 Mb away from a locus
recently reported as a candidate region for French familial
narcolepsy.12 According to the SNP genotype data of 45
unrelated Japanese living in the Tokyo area registered in
the HapMap project database, there is no LD between
NLC1 and the region reported in the French family study.
Therefore, the association of NLC1 with human narco-
lepsy is considered a novel observation.
The NLC1 region contains no known genes, but data-
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Figure 5. Effects of the microsatellite marker D21S0012m in the
promoter region and of SNP rs13046884 in the intron 1 of NLC1-
A on transcriptional activity. Reporter-gene constructs contained
the sequences from IVS131 to IVS1327 for rs13046884 or 80–
987 nt upstream of the transcription initiation site for D21S0012m.
The chart shows luciferase expression from each reporter in trans-
fected HeLa cells or NB-1 cells, relative to empty vector. Data are
means of at least three independent experiments. Error bars rep-
resent SDs.
bases show three predicted genes, which we tentatively
named “NLC1-A,” “NLC1-B,” and “NLC1-C.” Because of
the locations of the three most strongly associated
polymorphisms (D21S0012m in intron 1 of NLC1-A,
rs13046884 424 bp upstream of NLC1-A and in the 3′ UTR
of NLC1-B, and rs13048981 2,602 bp upstream of NLC1-
B), we focused onNLC1-A andNLC1-B. In RT-PCRanalysis,
NLC1-A, but not NLC1-B, was expressed in human hy-
pothalamus, which also expresses preprohypocretin,42 a
protein important in orchestrating the sleep-wake cycle.43
Therefore, we ﬁnally focused on NLC1-A, and we tested
whether the D21S0012m and rs13046884 polymorphisms
affect gene expression. In a reporter-gene assay, NLC1-A
fragments containing the alleles for narcolepsy resistance
(D21S0012m [CA]10 allele and rs13046884 g allele) were
less transcriptionally active than were those of other al-
leles. This ﬁnding supports the hypothesis that the poly-
morphisms of NLC1-A may be directly involved in resis-
tance to human narcolepsy.
A motif search of the putative NLC1-A protein, with the
use of MOTIF (GenomeNet) and Motif-Finder (RIKEN), re-
vealed a domain known as “binding-protein–dependent
transport systems inner membrane component.” Binding-
protein–dependent transport systems have been charac-
terized as members of a superfamily of transporters found
not only in bacteria but also in humans, and they include
both import and export systems.44 Therefore, NLC1-A
might function as a transporter of certain substances
(amino acids, sugars, large polysaccharides, or proteins).
A motif search of the cDNA sequence of NLC1-A was also
performed using MOTIF and Motif-Finder, and NLC1-A
includes domains known as integrin b-chain cysteine-rich
domain, anaphylatoxin domain, and epidermal growth
factor–1 domain signatures. Furthermore, the amino acid
sequence of NLC1-A was subjected to secondary structure
prediction (SOSUI program). NLC1-A has a long loop (res-
idues 78–125) with high hydrophilicity, ﬂexibility, and
surface probability, which suggests that NLC1-A may be a
membrane protein. No carbohydrate-modiﬁcation region
was predicted. The UCSC Genome Browser showed a
chimpanzee gene with 98% sequence identity to NLC1-A.
In contrast, there was no homologous gene in rodent or
canine genomes. Thus, NLC1-A is likely to exist only in
primates.
Recently, genomewide association analysis with hun-
dreds of thousands of SNPs has become realistic, but such
a systematic product was not available when we started
the present study. Therefore, we took a unique approach—
genomewide association analyses with highly polymor-
phic microsatellite markers that were selected every ∼100
kb throughout the human genome.33 Because pooled
DNAs were used in the ﬁrst and second screenings, the
typing cost was reasonable, even when 23,244 markers
were used.
Because human narcolepsy is a multifactorial disorder
for which the relative risks of individual associated genes
may not be particularly high, we hypothesize that several
more susceptibility/resistance genes remain to be eluci-
dated. Thirty microsatellite markers displayed association
with human narcolepsy in both ﬁrst and second screen-
ings. The observed associations of the microsatellitemark-
ers were not strong, and the markers were similar to each
other in the strength of association. Therefore, the re-
maining 29 uncharacterized regions may include other
susceptibility/resistance loci for narcolepsy. Some false-
positive results may still survive after both screeningswith
the use of pooled DNA samples, but most of them can be
excluded in subsequent high-density mapping and asso-
ciation analysis with additional cases and controls. An
association study with an entirely separate set of cases and
controls or replication studies in other populations and
transmission disequilibrium test may be preferred to com-
pletely eliminate false-positive associations, although the
detection power is decreased because additional as-
sociation studies lead to an increase in false-negative
associations.
In conclusion, a genomewide association studywith the
use of a dense set of microsatellite markers and pooled
DNA can be useful for the systematic search for candidate
regions of multifactorial disorders—such as human nar-
colepsy, rheumatoid arthritis (RA [MIM 180300]), type II
diabetes (NIDDM [MIM 125853]), hypertension (MIM
145500), psoriasis (MIM 177900), and schizophrenia
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(SCZD [MIM 181500])—for which pathophysiological
mechanisms remain unclear. We were able to detect 30
candidate microsatellite markers, among which one nar-
colepsy resistance gene, NLC1-A, was identiﬁed success-
fully. Functional analyses of NLC1-A are in progress, and
the remaining 29 candidate markers will be further
analyzed.
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